Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
INKT
STRONG SELLMiNK Therapeutics, Inc. · Healthcare · United States · $55M · Avg Vol: $171K/d
8
StockRankGet insider-trade alerts
Q
21
V
25
M
34
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Loading 1Y...
PRICE (1Y)-11.9%
SMA 50SMA 200
Close
$10.59
RSI (14)
49.7
52W High
$20.25
From 52W High
0.5%
SCORE BREAKDOWN
Quality
21
ROIC
-1063.1%0.2
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-35.9%8.2
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
—N/A
Current Ratio
1.38x22.0
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-3.6x25.0
P/FCF
—N/A
P/B
-4.3x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
34
52W High %
52%28.4
RS 6M
-23%40.8
SMA 50/200
0.97x58.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-2%20.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$55M
P/E (Forward)
-3.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of INKT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| INKT | MiNK Therapeutics, Inc.(you) | $55M | 8 | STRONG SELL |
| CNTX | Context Therapeutics Inc. | $56M | 10 | STRONG SELL |
| HYFT | MindWalk Holdings Corp. | $64M | 8 | STRONG SELL |
| DWTX | Dogwood Therapeutics, Inc. | $50M | 10 | STRONG SELL |
| GOSS | Gossamer Bio, Inc. | $66M | 8 | STRONG SELL |
| KALA | KALA BIO, Inc. | $63M | 9 | STRONG SELL |
| ATYR | aTyr Pharma, Inc. | $52M | 5 | STRONG SELL |
| TIL | Instil Bio, Inc. | $50M | 11 | STRONG SELL |
| ANVS | Annovis Bio, Inc. | $71M | 8 | STRONG SELL |
| TCRX | TScan Therapeutics, Inc. | $52M | 4 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%